Rigel Pharmaceuticals ((RIGL)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rigel Pharmaceuticals’ latest earnings call struck an optimistic tone, with management highlighting robust double‑digit product sales growth, disciplined execution and a clear path to full‑year profitability in 2026. While rising expenses, a dip in quarterly net income and some pipeline uncertainty tempered the picture, the company’s commercial momentum and strengthened balance sheet dominated the narrative.
Broad-Based Surge in Net Product Sales
Rigel reported Q1 2026 net product sales of $54.9 million, a 26% year‑over‑year increase and an $11.3 million gain versus Q1 2025. Management pointed to strengthening demand across the portfolio, especially in March, suggesting that early‑quarter reimbursement headwinds are already easing.
TAVALISSE Leads with Strong Outperformance
TAVALISSE remained the growth engine, delivering $37.3 million in Q1 net product sales, up 31% from a year earlier. The company credited both higher underlying demand and a more favorable gross‑to‑net dynamic compared with last year, underscoring the durability of this cornerstone asset.
REZLIDHIA Builds Rapid Growth and Momentum
REZLIDHIA matched TAVALISSE’s trajectory, generating $8.0 million in Q1 net product sales, also up 31% year over year. Commercial traction is broadening in academic centers, and Rigel is intensifying efforts to drive deeper adoption in community oncology practices, which could unlock further upside.
GAVRETO Remains a Stable but Slower Grower
GAVRETO contributed $9.6 million in Q1 net product sales, growing 7% from the prior year and holding near a $9–10 million quarterly run rate. Management characterized the franchise as a steady, recurring revenue source, but acknowledged that its growth profile is more plateau‑like than the rest of the portfolio.
Total Revenue Lifted by International Partnerships
Total revenue reached $58.8 million in Q1 2026, bolstered by $3.9 million of contract and collaboration income. Contributions from partners such as Grifols, Kissei and Medison are helping extend Rigel’s footprint internationally, adding a diversified revenue stream alongside core U.S. product sales.
Profitability Target Intact with Guidance Reaffirmed
Management reiterated 2026 guidance calling for $275–$290 million in total revenue, including $255–$265 million in net product sales and $20–$25 million in contract revenues. Crucially for investors, Rigel reaffirmed its expectation of delivering positive net income for the full year, reinforcing confidence in its scaling business model.
R289 Shows Encouraging Early Clinical Efficacy
On the R&D front, the IRAK1/4 inhibitor R289 produced promising Phase Ib dose‑escalation data in higher‑dose cohorts. Among 18 evaluable patients at doses of at least 500 mg, 6 achieved at least eight weeks of red cell transfusion independence with manageable safety, supporting continued development under existing Fast Track and Orphan Drug designations.
Operational Discipline and Balance Sheet Flexibility
Rigel highlighted continued operational discipline after achieving profitability in 2024 and entering Q1 2026 with $146.7 million in cash, equivalents and short‑term investments. The company also refinanced its debt into a $40 million revolving credit facility, with an option to expand to $60 million, providing flexible capital to support growth.
Business Development Aimed at Late-Stage Assets
Management outlined a clear business development strategy focused on in‑licensing or acquiring late‑stage hematology and oncology programs. The goal is to secure assets with potential launches over the next three years, allowing Rigel to leverage its existing commercial infrastructure and accelerate top‑line growth.
Net Income Declines Despite Strong Sales
Despite robust revenue, Q1 2026 net income fell to $8.7 million from $11.4 million a year earlier, a roughly 24% decline. The drop reflects higher operating spending as Rigel invests in R&D, commercial capabilities and personnel to support its expanding product base and pipeline.
Rising Costs and a Modest Cash Drawdown
Total costs and expenses climbed to $46.9 million in Q1 from $40.6 million last year, a 15.5% increase tied to R289 activities and broader commercial spending. Cash and investments slipped by about $8.3 million to $146.7 million, and Rigel has drawn $8 million on its new revolving facility, leaving ample liquidity but highlighting ongoing investment needs.
Seasonal Reimbursement Headwinds Pressure Q1
Management noted that Q1 results reflected typical seasonal reimbursement dynamics, including deductible resets and Medicare plan changes that dampened January and February volumes. They indicated that trends improved meaningfully in March and expressed confidence in a sequential rebound in Q2 as these headwinds fade.
GAVRETO’s Limited Upside Versus Other Brands
While GAVRETO remains a reliable contributor, its roughly 7% year‑over‑year growth and plateau around $9–$10 million per quarter suggest constrained long‑term upside. Investors may increasingly view it as a cash‑generating but mature asset, in contrast to the faster‑growing TAVALISSE and REZLIDHIA franchises.
Lilly Collaboration Ends, RIPK1 Path Unclear
A key setback came with Eli Lilly’s decision to terminate the collaboration around ocodusertib, Rigel’s RIPK1 program, effective mid‑June 2026. Rigel will regain rights to the asset, but the loss of partner support injects uncertainty into its future development, and management emphasized that no revenues from this program are included in current guidance.
R289 Opportunity Balanced by Data Limitations
Management was upbeat on R289’s potential but acknowledged that Phase Ib data remain based on a small cohort of 18 evaluable patients at higher doses. The ultimate registrational path will depend on forthcoming dose‑expansion results and regulatory feedback, with topline expansion data expected by year‑end 2026, leaving investors waiting for a more definitive readout.
Guidance Reinforces Growth and Profitability Narrative
Looking ahead, Rigel’s leadership reiterated its 2026 outlook, underscoring confidence in delivering $275–$290 million in total revenue and a profitable year. The forecast assumes continued strength from TAVALISSE and REZLIDHIA, steady GAVRETO contributions, modest contract revenue growth and disciplined spending, while excluding any upside from the now‑ended Lilly partnership.
Rigel’s earnings call painted the picture of a company in transition from small‑cap biotech to a more mature commercial player, powered by strong product growth and a clearer route to sustainable profitability. While higher spending, a few slower‑moving assets and pipeline uncertainties pose risks, management’s maintained guidance and strategic focus suggest the momentum remains in the company’s favor for now.